Hi Guys
I was just pondering the oncology landscape with a view to trying to work out what all the noise is about with Car T treatments ( ref the recent CHM listing etc & PTX ) ....vs whats IMU might hold in store & how the two companies fit into the over all landscape .
I'm not really much more enlightened , other than to conclude that the oncology landscape is huge and covers many many types of cancer .
Someone told me once that there are about a 1000 variants of cancer ...not sure if thats so or not .....but clearly there are lots and lots .
Different cancers require different approaches ....
Question : Is it realistic to think that IMU's B Cell / Vaccination approach might be applicable for the whole spectrum of cancers ???? - or just a few main ones ???
Answer : FIK .....but would love to hear feedback - or is the simply that only certain cancers are applicable targets for IMU's IP
As relates to Car T therapies ....... it seems that the treatments are horrendously expensive ...and I've seen articles quoting $300 k plus ( USD ) to a Million
see the links to articles about this
https://www.healio.com/news/hematol...otal-cost-can-exceed-15-million-per-treatmentIt would be really good to hear LC's view on all of this ...particularly as she has taken on a directorship with CHM .
ALSO FYI
see an OLD media article ref IMU 2018 ........ it is a good overview of where IMU began and the general mission they are embarking on
https://unauthorised investment adv...e-has-a-fighting-chance-in-its-cancer-battle/cheers
VA
